On January 23, 2025 AbbVie (NYSE: ABBV) reported that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie (Press release, AbbVie, JAN 23, 2025, View Source [SID1234649853]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Nimble’s lead asset is an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis. Additionally, Nimble’s peptide synthesis, screening, and optimization platform uses proprietary technology to help drive rapid discovery and optimization of oral peptide candidates for a range of targets.

"With the acquisition now complete, we are excited to expand our immunology pipeline to include Nimble’s novel oral peptide assets and look forward to integrating this proprietary technology into our R&D capabilities," said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. "We are pleased to welcome the talented team at Nimble who share our commitment to elevating the standard of care for people living with autoimmune diseases."